immune system, LXR agonists have robust anti-atherosclerotic activity in mouse (Joseph et al., 2002a; Terasaka et al., 2003) and rabbit models (Giannarelli et al., 2012; Vucic et al., 2012) .
LXRs also stimulate fatty acid synthesis and metabolism through the induction of SREBP1c, FAS, SCD1, and other genes (Schultz et al., 2000) . As a consequence, LXR activation can cause increased triglyceride (TG) synthesis and elevated VLDL secretion in liver, with resultant hypertriglyceridemia and hepatic steatosis. Other LXR target genes are also modulated in liver that result in inhibition of triglyceride lipolysis in the circulation, including angiopoietin-like 3 protein (Inaba et al., 2003) and apoAV (Jakel et al., 2004) . In addition, LXRs upregulate the expression of IDOL, an E3 ubiquitin ligase, which ubiquitinates the LDL receptor causing its degradation (Zelcer et al., 2009 ).
This mechanism has the potential to downregulate hepatic LDL receptors resulting in elevated circulating LDL. Increased production of VLDL and the induction of CETP mentioned above can also contribute to elevated LDL. Thus, multiple pathways are activated by LXR in liver which have the potential to cause hepatic steatosis and dyslipidemia and, indeed, LXR agonists, including GW3965 and T0901317, have been shown to increase liver and plasma TG and LDL in mouse and hamster models (Groot et al., 2005; Joseph et al., 2002b; Schultz et al., 2000) . More limited results of LXR lipid effects have been reported in primates with variable responses, depending on the compound and study (Groot et al., 2005; Quinet et al., 2009 ).
These undesirable effects on plasma lipids have been the major impediment for the development of LXR agonist therapeutics. It is likely that LXRα is the isoform that mediates most of the hepatic effects, at least in mice, since LXRα null mice have reduced lipogenic responses to pan agonists (Lund et al., 2006;  J P E T # 2 1 9 9 2 3 9 performed in an MJ Thermocycler in 40 µl reaction volumes using a Bio-Rad iScript™ cDNA Synthesis Kit and then added to Sybr-Green reactions using iTaq™SYBR® Green Supermix with ROX (Bio-Rad, Hercules, CA) according to the supplier. Forward and reverse PCR primers for each gene are included (Supplemental Table 1 ). The relative amount of each LXR target gene mRNA was calculated using the second derivative comparative Ct method (2 -∆∆Ct ). Quantification was obtained after normalization to the internal standard ribosomal protein L30 mRNA and confirmed with a second standard mRNA for β 2 microglobulin. Each sample was tested in duplicate wells and the average Ct was used for calculations.
Liver TG measurements by MRS. The effect of BMS-779788 on liver TG was determined at baseline and 24 hrs following the 7th dose (day 7) by MR spectroscopy according to the method of Szczepaniak et al. (Szczepaniak et al., 2005) . All in vivo MR spectroscopic measurements were made using the following procedure with a Bruker 4.7T/40cm MRI system (Bruker BioSpin Corp., Billerica, MA).
After prepping the animal for MR imaging by a veterinary anesthesiologist, the animal was placed in the magnet. Scout images were collected using RARE tripilot pulse sequence of the abdominal area including the liver using coronal and axial orientations. Using the scout images, subsequent axial and coronal images were obtained using the following instrument settings: For axial scout images:
FOV=12cm; 15 slices; 3mm slice thickness; TR/TE = 500/15ms and a matrix of 256x256. For coronal scout images: FOV=20cm; 17 slices; 3mm slice thickness; TR/TE = 1200/18ms and a matrix of 256x256. Localized MR spectroscopy of a 12mm voxel in the center of the liver was performed using a PRESS pulse sequence and the data acquisition was carried out with and without water suppression.
Respiratory gating was used during data acquisition. Respiratory gated MR spectra of the 12mm liver voxel were collected using a TR/TE of 3000/15ms with water suppression for 256 and 512 averages. In addition to the water suppressed acquisition, an unsuppressed spectrum was also acquired using 256
averages.
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Quantitation of BMS-779788 in plasma and liver samples. The mass spectrometer used for quantitative analysis was a MDS Sciex API-3000 triple quadrupole equipped with a turbo ion spray source (Toronto, Canada). Plasma samples were treated with 3 volumes of methanol containing an internal standard. After centrifugation, the supernatant was further diluted with water 5 fold prior to analysis using LC/MS/MS. The LC system used was an Aria TX-2 TurboFlow® (Cohesive Technologies, Franklin, MA, USA) with a Waters Atlantis C18 column using a five-minute gradient. All standard curves were fitted using linear regression weighted by the reciprocal of concentration squared.
Liver homogenate samples were first diluted with blank plasma and then quantified together with plasma samples against plasma standard curves. 
Results
The structure and in vitro properties of BMS-779788 have been described elsewhere (Kick et al., 2014) .
Briefly, it has modest human LXRβ binding selectivity (IC 50 = 68 and 14 nM, for LXRα and LXRβ, respectively) with 38% LXRα and 72% LXRβ activity in whole receptor functional transactivation assays, compared to a full agonist. The EC 50 for endogenous ABCA1 & ABCG1 gene induction in an in vitro human whole blood assay (WBA) is 1 µM for each, and its efficacy is 45% and 55%, respectively.
In an equivalent cynomolgus monkey assay, EC 50 s are 140 nM and 340 nM, with efficacies of 41% and 73% respectively. Consistent with its partial activity, BMS-779788 has 50% of the activity compared to T0901317 in a human THP1 macrophage cholesterol efflux assay. T0901317, the full LXRα/β dual reference agonist used in these studies, has equal binding potency for both human receptors (IC 50 = 45 nM for each), and is a full agonist in both LXRα and LXRβ transactivation assays. It is a full agonist with an EC 50 = 305 nM in the cynomolgus monkey whole blood assay.
In an initial study to characterize the relationship between BMS-779788 plasma exposure and ABCG1 mRNA induction in blood cells, we performed a single dose PK-PD study in male cynomolgus monkeys. Following a 1 mg/kg oral dose, the time course of plasma compound concentration and ABCG1 mRNA induction mirrored each other out to 24 hrs (Fig 1) . The Tmax for BMS-779788 and gene induction was 2 hrs with a Cmax of 2227 nM and a maximal ABCG1 induction of 4.7 fold.
ABCG1 mRNA levels were back to near baseline by 24 hrs and the BMS-779788 plasma concentration was 154 nM by 48 hrs. ABCA1 mRNA levels are not shown for reasons described below.
A repeat dosing study of BMS-779788 was then performed to determine the exposure-response for the induction of ABCG1 in blood vs. the effect on plasma lipids, apo B, and CETP. This was compared to the effects of a 10 mg/kg/d dose of T0901317. BMS-779788 was given orally at 0.3, 1, 3, and 10 mg/kg/d, along with T0901317 and vehicle control, qd for a total of 7 days. Table 1 shows the plasma J  P  E  T  #  2  1  9  9  2  3 1 2 levels for both compounds at 5 hrs post-dose on days 1, 4, and 7, in nM concentration as well as fold over the cynomolgus monkey WBA EC 50 . BMS-779788 exposure was dose-proportional, ranging from 1.8 to 28.4 fold over its EC 50 on day 1, and 0.8 to 20.2 fold on day 7. T0901317 exposure was 1.0 and 0.7 fold over its EC 50 on days 1 and 7, respectively. Therefore, plasma levels of both compounds were sufficient for partial to full LXR target engagement in this repeat dosing study.
We next determined ABCG1 mRNA induction in blood at 5 hours post-dose on days 1 and 7 (Fig 2A) .
BMS-779788 treatment caused a dose-dependent induction from 6.7 to 12.8 fold vs. baseline on day 1, and 4 to 14.3 fold on day 7. T0901317 induced ABCG1 7.6 and 6.3 fold on days 1 and 7, respectively.
At comparable exposures plotted as a function of fold over their respective WBA EC 50 values, both compounds showed similar blood ABCG1 induction (Fig. 2B) . In order to explore the effects of a broader dose range on ABCG1 mRNA and to determine the potency of the compound in vivo, animals were dosed for 5 hours with vehicle or 0.1 to 10 mg/kg BMS-779788, and blood ABCG1 mRNA levels and plasma compound levels were determined. The in vivo EC 50 for ABCG1 induction was 630 nM (Supplemental Figure 1) , a value similar to the 340 nM potency seen in the in vitro WBA. The effect of the LXR agonists on blood ABCA1, the other major cholesterol efflux transporter, was also determined in the 7 day repeat dosing study above (Supplemental Figure 2) . In all studies that we have performed in cynomolgus monkeys including those reported here, we observe an induction of ABCA1 mRNA in vehicle treated animals (2 to 3 fold in this study). This appears to be a procedural effect of unknown mechanism due to gavaging, since similar effects were observed when dosing water (data not shown). It is possible that an interaction occurs between LXR agonists and this procedural effect since we often do not see clear compound dose-responses in ABCA1 induction. Thus, we have used blood ABCG1, and not ABCA1 mRNA as our PD biomarker in this model.
Next we determined the effect of BMS-779788 on plasma lipids on days 4 and 7 and compared it to T0901317. Exposure-dependent increases in TG above baseline (11 to 298%) and LDL-C (10% to 101%) were observed in BMS-779788 treated animals on day 7 (Fig. 3) . By comparison, the full pan agonist T0901317 caused marked increases in TG (293%) and LDL-C (51%) at much lower exposures than those that resulted in similar changes with BMS-779788 (29 and 12 fold lower for TG and LDL-C, respectively). Similar patterns were observed for plasma apo B and CETP mass (Fig. 4) . Effects on HDL-C were similar for both compounds (Fig. 3) . The difference in the plasma lipid therapeutic indices between these two compounds is evident in Fig. 5 in which ABCG1 mRNA and plasma lipids on day 7
are plotted. T090137 exposures of 0.7 x WBA EC 50 resulted in 6.3 fold ABCG1 induction and 293%
and 51% increase from baseline for plasma TG and LDL-C, respectively. By comparison, BMS-779788 at approximately 4 fold higher exposure (2.7 x WBA EC 50 ) resulted in similar ABCG1 induction (7.2 fold) with little effect on TG (12% increase) and LDL-C (3% increase). The time course of effects on plasma TG, LDL-C, total cholesterol, and HDL-C weremeasured on days 2, 4, and 7 (Supplemental Due to their induction of hepatic lipogenic pathways, increased liver TG has been observed in LXR agonist treated mice, hamsters, and cynomolgus monkeys. In a separate 7 day cynomolgus monkey study, the change from baseline in hepatic TG following treatment with vehicle or 0.3, 1, and 10 mg/kg/d BMS-779788 was determined using magnetic resonance spectroscopy, and compared with changes in plasma TG ( was also determined (Fig. 7) . Two doses, 1 and 10 mg/kg/d, were the same as the top 2 doses in the previous study. The hepatic drug exposure at 24 hrs post-dose was <LLQ, 3.4 µM (14 fold WBA EC 50 ), and 40.9 µM (170 fold WBA EC 50 ) at these 3 doses. Dose-dependent increases in the lipogenic genes SREBP1c, FAS, SCD1, and Angptl3 were apparent, consistent with the dose-dependent increase in liver and plasma TG in the above magnetic resonance spectroscopy study. Furthermore, the response of these genes at 1 and 10 mg/kg/d is consistent with the relative TG and LDL-C response at these doses in the 7 day PD study. The cholesterol efflux transporters, ABCG5 and ABCG8, were also modestly induced in liver, a result similar to the reported inductions in mouse by full pan agonists (Repa et al., 2002) .
Previous studies in mouse have shown an induction of LPL in liver that could account for a blunting of elevated plasma TGs due to increased clearance of TG rich lipoprotein particles (Peng et al., 2010; Zhang et al., 2001) . In these studies, no effect of BMS-779788 on cynomolgus monkey hepatic LPL mRNA was observed, suggesting that this effect may not translate to higher species.
LXR agonists have the potential to change biliary lipid composition, due to their effects on hepatic biliary cholesterol secretion via hepatic ABCG5 and ABCG8 mRNA induction. Bile composition in vehicle and BMS-779788 treated male monkeys was determined following 2 weeks of treatment as part of the same toxicology study described above ( jpet.aspetjournals.org Downloaded from
Discussion
The LXRβ selectivity strategy for avoiding undesirable lipid effects is based on mouse studies. Dual LXR agonists including T0901317, GW3965, and others cause triglyceridemia and liver steatosis in wild type animals but this response is largely absent in mice lacking LXRα. However, the mouse differs significantly from human in several key aspects of lipoprotein metabolism, whereas the cynomolgus monkey is more human-like. Unlike the mouse, cynomolgus monkeys express CETP and, therefore, should better predict LXR agonist effects on cholesterol trafficking between HDL and LDL in humans.
In addition, mouse and rat CYP7A1, the rate limiting enzyme for bile acid synthesis by the classical gene, and an activity that is likely to play a significant role in LXR-dependent LDL-C elevations. As was the case with TG, LDL-C, apo B, BMS-779788 was also less potent in CETP mass elevation.
While this improved profile of BMS-779788 is consistent with the LXRα hypothesis of lipogenesis, other properties of the compound including its overall partial activity in whole blood target gene induction may also contribute to the favorable profile in non-human primates. Partial agonists can display tissue-specific activation or repression of nuclear receptors, as has been shown for the estrogen receptor partial agonist raloxifen (Delmas et al., 1997) . The basis for tissue selectivity of NHR partial agonists is incompletely understood but probably relates to differential competitive recruitment of coactivators and corepressors (Albers et al., 2006) . Hepatic exposure differences between T0901317 and BMS-779788 could also potentially contribute to differences in lipogenic responses.
The effects of another LXR agonist, WAY-252623, in cynomolgus monkeys has also been reported (Quinet et al., 2009) . This compound has an in vitro profile similar to BMS-779788 with 7 fold
LXRβ binding selectivity and partial LXRα activity (Wrobel et al., 2008) . However, instead of elevating lipids, WAY-252623 decreased plasma LDL-C and only transiently increased plasma TG. The mechanism for this result is unclear, however it seems unlikely that it is related to the LXRα partial activity of the compound. The authors suggest that it may be due to its induction of intestinal FGF19 expression. Then again, GW3965, which elevates LDL-C and TG in cynomolgus monkeys, also induced FGF19. The molecular pharmacology underlying the unexpected plasma lipid lowering by this agonist requires more investigation.
The effect of LXR agonists on liver and circulating TG is multi-facetted with regulation in liver of both fatty acid and TG synthesis and lipolysis pathways. The TG synthesis genes SREBP1c, FAS, and SCD1 are induced while angptl3, which blocks lipolysis, is upregulated. BMS-779788 treatment increased liver TG in a dose-response that mirrored plasma TG changes, and that was consistent with the doseresponse of the lipogenic genes SREBP1c, FAS, and SCD1 in liver. In the mouse, LXR also has proThis article has not been copyedited and formatted. The final version may differ from this version. lipolytic effects through the induction of LPL in liver, an organ that doesn't ordinarily express LPL. This has the potential to limit LXR-dependent hypertriglyceridemia but also to potentiate liver TG accumulation through re-directing LPL-derived fatty acids back into liver. However, this does not appear to be the case in cynomolgus monkeys since no hepatic induction of LPL by BMS-779788 was observed. Therefore, primates may lack this regulation of TG metabolism by LXR.
In bile, cholesterol is maintained in soluble form by bile acids and phospholipids. When the ratio of biliary cholesterol to these solubilizing agents increases, the maximal soluble cholesterol concentration decreases and, if it rises above the saturation limit, gall stone formation can occur. Treatment of mice with T0901317 caused increased biliary cholesterol and decreased phospholipid and bile acids (Yu et al., 2003) , however effects on cholesterol saturation was not explored in this study. BMS-779788 treatment also elevated biliary cholesterol and lowered phospholipid and bile acids in our primate studies. When the cholesterol saturation index, a measure of lithogenic potential, was calculated using published critical tables, a dose-dependent increase in CSI was observed following 2 weeks of treatment, reaching 310% of maximal soluble biliary cholesterol at the top dose. In other words, biliary cholesterol was 3 fold higher than its solubility limit. While we did not examine gallstone formation in this study, this suggests that LXR agonists could be lithogenic at high doses in the clinical setting.
In summary, BMS-779788, a novel LXRß selective agonist, has a markedly improved plasma lipid profile compared to a dual agonist in a cynomolgus monkey model. This data in non-human primates lends further support to the concept of restricting LXRα activity in order to avoid the undesirable lipid effects of LXR agonists. : 7 6 0 4 -7 6 0 9 . V e n k a t e s w a r a n A , This article has not been copyedited and formatted. The final version may differ from this version.
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In vivo potency of BMS-779788. Cynomolgus monkeys were dosed for 5 hours with vehicle or 0.1 to 10 mg/kg BMS-779788, and blood ABCG1 mRNA levels and plasma compound levels were determined. The potency of the compound was calculated by fitting a sigmoidal curve with fixed slope =1 (GraphPad Prism 5.0) to a plot of log M compound vs. fold ABCG1 induction. Time and dose-dependent effects of BMS-779788 and T0901317 on plasma lipid values in 7 day cynomolgus monkey study. Animals were dosed orally, q.d. for 7 days with LXR agonists at doses in mg/kg/d indicated in parentheses. TG, LDL-C, total cholesterol, and HDL-C (in mg/dl) were measured in plasma from blood drawn at day -1 (baseline) and 24 hours post-dose on days 2, 4, and 7. *, p<0.05; **, p<0.01 vs. baseline. +, p<0.05; ++, p<0.01 vs. vehicle treated. 
